Not Yet Recruiting PHASE3 INTERVENTIONAL 2-arm NCT07133802

Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination

A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine in Adults Aged 18-59 Years

Sponsor: Center for Disease Control and Prevention, Fujian

Conditions Prevention of Influenza

Interventions Placebo Group Test Group

Updated 1 time since 2025 Last updated: Aug 14, 2025 Started: Aug 31, 2025 Primary completion: Mar 31, 2026 Completion: Jul 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Prevention of Influenza and is currently actively recruiting participants. Center for Disease Control and Prevention, Fujian leads this study, which shows 1 recorded version since 2025 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

1 version recorded

Not Yet Recruiting — PHASE3 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Center for Disease Control and Prevention, Fujian
Changchun BCHT Biotechnology Co.
Hubei Provincial Center for Disease Control and Prevention
Zhejiang Provincial Center for Disease Control and Prevention

Data source: Changchun BCHT Biotechnology Co.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.